{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:52:36Z","timestamp":1793436756370,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014434","name":"Narodowa Agencja Wymiany Akademickiej","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023181","name":"Agencja Bada\u0144 Medycznych","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.euf.2025.03.019","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T23:41:12Z","timestamp":1747352472000},"page":"755-766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"11","author":[{"given":"Marcin","family":"Miszczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Leapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V.","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.03.019_b0005","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","article-title":"Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"82","author":"Yanagisawa","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.03.019_b0010","series-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer","author":"Cornford","year":"2024"},{"key":"10.1016\/j.euf.2025.03.019_b0015","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":"Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0020","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/djj129","article-title":"Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16","volume":"98","author":"Petrylak","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2025.03.019_b0025","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2013.50.3201","article-title":"Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy","volume":"31","author":"Halabi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0030","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1200\/JCO.2005.08.156","volume":"23","author":"Collette","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0035","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","article-title":"Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group","volume":"17","author":"Bubley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0040","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0045","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.2011.39.1300","article-title":"Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer","volume":"30","author":"Nelson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/pcan.2016.71","article-title":"Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL","volume":"20","author":"Bryce","year":"2017","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2025.03.019_b0055","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/pros.24588","article-title":"Real-world analysis of metastatic prostate cancer demonstrates increased frequency of PSA-imaging discordance with visceral metastases and upfront ARAT\/docetaxel therapy","volume":"83","author":"Hara","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2025.03.019_b0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.euo.2024.04.009","article-title":"Radiographic progression without corresponding prostate-specific antigen progression in patients with metastatic castration-sensitive prostate cancer receiving apalutamide: secondary analysis of the TITAN trial","volume":"8","author":"Fukuokaya","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euf.2025.03.019_b0065","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1200\/JCO.2022.40.16_suppl.5072","article-title":"Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of ARCHES","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0070","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.euo.2024.04.004","article-title":"The state of intermediate clinical endpoints as surrogates for overall survival in prostate cancer in 2024","volume":"7","author":"Miszczyk","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0075","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.03.019_b0080","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.03.019_b0085","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.euf.2025.03.019_b0090","unstructured":"Rohatgi A. WebPlotDigitizer v.4.6. https:\/\/automeris.io\/."},{"key":"10.1016\/j.euf.2025.03.019_b0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euf.2025.03.019_b0100","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euf.2025.03.019_b0105","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.03.019_b0110","doi-asserted-by":"crossref","first-page":"S1162","DOI":"10.1016\/j.annonc.2022.07.1493","article-title":"1361MO\u20038-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial","volume":"33","author":"Gravis Mescam","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","volume":"86","author":"Saad","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.03.019_b0120","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/bju.16449","article-title":"Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy","volume":"134","author":"Merseburger","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.03.019_b0125","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.euf.2025.03.019_b0130","doi-asserted-by":"crossref","first-page":"S964","DOI":"10.1016\/j.annonc.2023.09.2734","article-title":"1784P\u2003Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS","volume":"34","author":"Saad","year":"2023","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.euf.2025.03.019_b0135","doi-asserted-by":"crossref","first-page":"S776","DOI":"10.1016\/S0302-2838(22)00600-5","article-title":"A0517 \u2013Clinical outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with prostate-specific antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): post hoc analysis of ARCHES","volume":"81","author":"Stenzl","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.03.019_b0140","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2021.11.020","article-title":"Deep prostate-specific antigen response following addition of apalutamide to ongoing androgen deprivation therapy and long-term clinical benefit in SPARTAN","volume":"81","author":"Saad","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.03.019_b0145","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/JU.0000000000003084","article-title":"Nadir prostate-specific antigen as an independent predictor of survival outcomes: a post hoc analysis of the PROSPER randomized clinical trial","volume":"209","author":"Hussain","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.03.019_b0150","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-14-1549","article-title":"Correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate-treated castration-resistant prostate cancer patients","volume":"21","author":"Xu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2025.03.019_b0155","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/cncr.30587","article-title":"Clinical outcomes and survival surrogacy studies of prostate\u2010specific antigen declines following enzalutamide in men with metastatic castration\u2010resistant prostate cancer previously treated with docetaxel","volume":"123","author":"Armstrong","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.03.019_b0160","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.euo.2018.11.005","article-title":"Prognostic association of prostate-specific antigen decline with clinical outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide in a randomized clinical trial","volume":"2","author":"Armstrong","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euf.2025.03.019_b0165","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1200\/JCO.2024.42.16_suppl.5079","article-title":"Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: landmark analysis of ENZAMET (ANZUP 1304)","volume":"42","author":"McLaughlin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euf.2025.03.019_b0170","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1200\/JCO.2022.40.16_suppl.5076","article-title":"Survival analysis of the randomized phase II trial to investigate androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415","volume":"40","author":"Maluf","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0175","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.euo.2023.11.015","article-title":"Post hoc analysis of rapid and deep prostate-specific antigen decline and patient-reported health-related quality of life in SPARTAN and TITAN patients with advanced prostate cancer","volume":"7","author":"Small","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0180","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/JU.0000000000004158","article-title":"Early prostate-specific antigen response by 6 months is predictive of treatment effect in metastatic hormone sensitive prostate cancer: an exploratory analysis of the TITAN trial","volume":"212","author":"Roy","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.03.019_b0185","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2025.03.019_b0190","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.03.019_b0195","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12254-022-00857-y","article-title":"Theranostics in prostate cancer","volume":"16","author":"Lipp","year":"2023","journal-title":"Memo"},{"key":"10.1016\/j.euf.2025.03.019_b0200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.03.019_b0205","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2025.03.019_b0210","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0215","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.03.019_b0220","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0225","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.03.019_b0230","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/s41591-024-03204-2","article-title":"Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial","volume":"30","author":"De Laere","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.euf.2025.03.019_b0235","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-22-2998","article-title":"Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer","volume":"29","author":"Tolmeijer","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2025.03.019_b0240","doi-asserted-by":"crossref","unstructured":"Torquato S, Pallavajjala A, Goldstein A, et al. Genetic alterations detected in cell-free DNA are associated with enzalutamide and abiraterone resistance in castration-resistant prostate cancer. JCO Precis Oncol 2019;3:PO.18.00227. https:\/\/doi.org\/10.1200\/PO.18.00227.","DOI":"10.1200\/PO.18.00227"},{"key":"10.1016\/j.euf.2025.03.019_b0245","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/s41467-023-37647-x","article-title":"Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning","volume":"14","author":"de Jong","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.euf.2025.03.019_b0250","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-22-2228","article-title":"SPOP mutations as a predictive biomarker for androgen receptor axis-targeted therapy in de novo metastatic castration-sensitive prostate cancer","volume":"28","author":"Swami","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925000756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925000756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:37:37Z","timestamp":1777955857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925000756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2405456925000756"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.03.019","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}